Development of Novel Chromeno[4,3-C]pyrazol-4(2h)-one Derivates Bearing Sulfonylpiperazine As Antitumor Inhibitors Targeting PI3Kα.

Yong Yin,Shao Sha,Xun Wu,She-Feng Wang,Fang Qiao,Zhong-Cheng Song,Hai-Liang Zhu

DOI: https://doi.org/10.1016/j.ejmech.2019.111630

IF: 7.088

2019-01-01

European Journal of Medicinal Chemistry

Abstract:A series of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates contained sulfonamido were designed and synthesized, and their anticancer effects in vitro was evaluated to develop some new PI3Kα inhibitors. Most of desired compounds exhibited the better antiproliferative activities against four cancer cell lines than that of LY294002. Out of them, compound 4o displayed the potent antiproliferative activity and high selectivity against the PI3Kα protein and it can induce apoptosis of HCT116 in a dose-dependent manner. Western blot assay indicated that compound 4o obviously down-regulated expression of p-Akt (S473). Molecular docking was performed to clarify the possible binding mode between compound 4o and PI3Kα. All these results indicated that compound 4o could be a potential inhibitor of PI3Kα.